Clinical Trial Update: A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of high-dose genetically targeted enzyme replacement therapy for advanced heart failure was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Ischemic Cardiomyopathy
• Non-ischemic Cardiomyopathy

Drugs mentioned

• Genetically Targeted Enzyme Replacement Therapy (high-dose)

Snippet

Sponsor: Celladon Corporation | Conditions: Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy | Phase 1, Phase 2 | Status: TERMINATED